Aldeyra Therapeutics Accounts Payable

Aldeyra Therapeutics's accounts payable stands at $140B as of March 2026. That compares with $350B in the prior-year period — down 59.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Aldeyra Therapeutics reported $140B in accounts payable versus $350B a year earlier — a 59.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $350B in the prior-year period — down 59.2% year over year. Sustained growth in accounts payable can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Aldeyra Therapeutics's accounts payable evolved across reporting periods, while the comparison chart places ALDX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, accounts payable is commonly used to spot outliers. Aldeyra Therapeutics's reading of $140B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.